CYDY lowered price for Leronlimab to $ 35,000, at the same time NP says BP returned to negotiating table
With lower price and approved combo, Leronlimab can be used off-label and compete with Gilead and others before the mono is approved

This is a good plan and thus pressing BP and before the mono is approved, off-label is most common in HIV, cancers and pediatrics